Hong Kong opens clinical data to strengthen drug approvals

Real-world evidence could support faster reviews, but cross-border data rules and post-approval access remain critical to Hong Kong’s launch ambitions.

Hong Kong is expanding the use of clinical data to support drug approvals and real-world studies, but regulatory speed alone will not determine whether the city becomes a stronger pharmaceutical and medtech launch market.

Vandana Iyer, Research Director at Frost & Sullivan, said there is no official estimate for how much real-world evidence can shorten approval timelines. However, Hong Kong’s 1+ mechanism targets a 150-working-day review and allows approval from one recognised reference regulator, supplemented by clinical studies, real-world evidence, and case reports.

“The real-world evidence benefit is not just in shortening approval timelines, but it's in contextualising the healthcare outcomes for the local population as well as the Asian patient,” Iyer said.

For pharma and medtech sponsors, predictability across the entire approval process will be critical. Iyer pointed to phased primary evaluation, the Real World Study and Application Centre, and Greater Bay Area support for trial design, institution matching, and recruitment.

She said Hong Kong would become more attractive if sponsors can access standardised research-ready data, faster ethics approval, and contracting, and a clearer path from registration to clinical adoption.

Cross-border data use remains a constraint. Iyer said the bottleneck spans consent, legal classification, contracting, cybersecurity, interoperability, and institutional risk tolerance rather than a single data-sharing mechanism.

Post-approval access presents another test. By February 2026, 19 drugs had gone through the 1+ mechanism, but only seven had entered the Hospital Authority drug formulary.

Faster approvals can strengthen Hong Kong’s position, Iyer said, but only if they are matched by formulary access, clinical research, Greater Bay Area studies, and patient uptake.

For Hong Kong, the opportunity lies in connecting data access, predictable regulation, and post-approval adoption into one launch pathway.